Verrica Pharmaceuticals Inc. (VRCA)
NCM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
Verrica seeks shareholder votes on board, pay, and stock plan amendments
# 📜 What This Document Is 🗓️ This document is a Proxy Statement (DEF 14A), which is essentially the company's official rulebook and agenda for its annual meeting of stockholders. It is not a financial results report, but rather a comprehensive legal filing that tells you exactly what decisions the
SEC filings
All filings →Insider trades
All insider trades →Verrica Pharmaceuticals Inc. has no reported insider trades in the last 90 days.